Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

RENESE-R

POLYTHIAZIDE; RESERPINE

Standard Dose
2MG;0.25MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview RENESE-R is listed in Drugs@FDA under application 013636 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient POLYTHIAZIDE; RESERPINE Form and strength TABLET;ORAL - 2MG;0.25MG Sponsor PFIZER Submission history Latest submission status date: 1992-06-26 00:00:00.

Structured Monograph

Clinical summary

Approval overview RENESE-R is listed in Drugs@FDA under application 013636 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient POLYTHIAZIDE; RESERPINE Form and strength TABLET;ORAL - 2MG;0.25MG Sponsor PFIZER Submission history Latest submission status date: 1992-06-26 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.